The bioavailability of glyburide (glibenclamide) under fasting and feeding conditions: A comparative study

被引：0

作者：

Otoom S. ^{[1
]}

Hasan M. ^{[1
]}

Najib N. ^{[2
]}

机构：

[1] Faculty of Medicine, Jordan University of Science and Technology, Irbid

[2] Faculty of Pharmacy, Jordan University of Science and Technology, Irbid

来源：

International Journal of Pharmaceutical Medicine | 2001年 / 15卷 / 3期

关键词：

Bioavailability; Fasting conditions; Food; Glibenclamide; Glyburide; Pharmacokinetics;

D O I：

10.1097/00124363-200106000-00003

中图分类号：

学科分类号：

摘要：

This investigation was conducted to study the effect of food on the oral absorption and disposition of glyburide (glibenclamide). The study was carried out under US Food and Drug Administration guidelines on 18 healthy male volunteers, under fasting and feeding conditions using a single oral dose (5 mg tablet) of glyburide. Following drug administration, blood samples were collected over 24 h, and serum harvested from the blood was analysed using a sensitive and specific high-performance liquid chromatographic assay. The results of this investigation indicated that there was a statistically significant difference in the concentration-time profiles of the drug and the obtained pharmacokinetic parameters under fasting and feeding conditions. In fasting conditions, area under the serum concentration-time curve for 24h and peak serum concentration were significantly higher than feeding conditions. Lag time between administration and appearance of the drug in serum was significantly reduced in fasting conditions compared with feeding situations. There was no significant difference in the time needed to reach peak concentration. These findings clearly indicate that the extent and rate of glyburide absorption is delayed when administered under feeding conditions. The study demonstrates the importance of administration of the drug on empty stomach to achieve a better pharmacokinetic profile.

引用

页码：117 / 120

页数：3

共 20 条

[1]

Gerich J.E., Oral hypoglycemic agents, N Engl J Med, 321, pp. 123-145, (1989)

[2]

Budaveri S., Neil M.J., Smith A., Heckelman P.E., The Merck index, 11th edn, (1989)

[3]

Melander A., Lebovitz H.E., Faber O.K., Sulfonylureas. Why, Which and How?, Diabetes Care, 13, pp. 18-25, (1990)

[4]

Groop L.C., Groop P.H., Stenman S., Saloranta C., Totterman K.J., Fyhrquist F., Melender A., Comparison of pharmacokinetics, metabolic effects and action of glyburide and glipizide during long-term treatment, Diabetes Care, 10, pp. 71-79, (1987)

[5]

Groop L.C., Sulfonylureas in NIDDM, Diabetes Care, 15, pp. 737-754, (1992)

[6]

Francisco G.E., Antidiabetic agents, Prim Care, 17, pp. 499-519, (1990)

[7]

Groop L.C., Barzilai N., Ratheiser K., Luzi L., Wahlin-Boll E., Melander A., DeFronzo R.A., Dose-dependent effect of glyburide on insulin secretion and glucose uptake in humans, Diabetes Care, 14, pp. 724-731, (1991)

[8]

Neugebauer G., Betzien G., Hrstka V., Kaufmann B., Von-Mollendroff E., Abshagen U., Absolute bioavailability and bioequivalence of glibenclamide (semi-euglucon), Int J Clin Pharmacol Ther Toxicol, 23, pp. 453-460, (1985)

[9]

Prendergast B.D., Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents, Clin Pharm, 3, pp. 473-485, (1984)

[10]

Marchetti P., Giannareli R., Di Carlo A., Navalesi R., Pharmacokinetic optimization of oral hypoglycemia therapy, Clinical Pharmacokinet, 21, pp. 308-317, (1991)

← 1 2 →